Search Results for "Tradjenta"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Tradjenta. Results 1 to 2 of 2 total matches.
See also: linagliptin
In Brief: Trijardy XR - A New 3-Drug Combination for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
Ther 2014;
56:99.
2. Linagliptin (Tradjenta) – a new DPP-4 inhibitor for type 2 diabetes.
Med Lett ...
The FDA has approved Trijardy XR (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose
cotransporter 2 (SGLT2) inhibitor empagliflozin, the
dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, and
extended-release metformin, for oral treatment of type 2
diabetes in adults. Empagliflozin and linagliptin have been
available in a fixed-dose combination as Glyxambi since
2015, and both have been available in 2-drug combinations
with extended-release metformin for years (see Table 1).
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
/day26 195.00
Nesina (Takeda) 409.00
Linagliptin – Tradjenta (Boehringer Ingelheim) 5 mg tabs 5 mg PO ...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.